Actionable news
0
All posts from Actionable news
Actionable news in ECYT: Endocyte, Inc.,

Regulation FD

The information contained in this Item 7.01 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

On March 31, 2016 the United States Seventh Circuit Court of Appeals issued a final order with mandate to dismiss the shareholder class action lawsuit filed in 2014 against Endocyte Inc., a leader in developing small molecule drug conjugates, and certain of its officers, directors and underwriters in connection with the events leading up to cessation of the PROCEED Phase 3 clinical trial.

On April 19, 2016the United States District Court for the Southern District of Indiana dismissed, without prejudice, the shareholder derivative lawsuit that was filed in 2014 against all of Endocytes current directors.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Endocyte, Inc.

By:

/s/ Beth A. Taylor

Name: Beth A. Taylor

Title: Corporate Controller

makes a similar move, sign up!

Other recent filings from the company include the following:

Endocyte Announces Promising Preclinical Data For Application Of Smdc Technology In Car T Cell Therapy In Late-Breaking Abstract At American Association For Cancer Research (Aacr) Annual Meeting 2016 - April 19, 2016